The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Metformin has been prescribed for type 2 diabetes for nearly 70 years. The hypothesis that it might extend healthy human lifespan is less than 20 years old — and the evidence for it is stronger than for almost any other longevity compound.
The longevity metformin story starts with epidemiology. Diabetic patients on metformin tend to outlive diabetic patients on other medications. This could be explained by metformin's cardiovascular benefits relative to alternatives. But the Bannister 2014 study in the UK Clinical Practice Research Datalink went further: T2D patients on metformin monotherapy had lower all-cause mortality than matched non-diabetic controls from the general population. The effect persisted after controlling for major confounders. If this finding reflects a true pharmacological effect, it suggests metformin produces health benefits that more than compensate for the burden of having type 2 diabetes — in effect, that metformin is making a disease population healthier than healthy people. This was the finding that convinced Nir Barzilai that a large controlled longevity trial was justified.
The mechanism that makes metformin biologically interesting for aging is AMPK activation. AMPK (AMP-activated protein kinase) is the cell's master metabolic sensor — it responds to energy deficit (high AMP:ATP ratio) and switches the cell from anabolic to catabolic mode: switching off protein synthesis, cell growth, and fat storage; switching on fatty acid oxidation, autophagy, and glucose uptake. This is the same pathway activated by caloric restriction, fasting, and exercise. Metformin activates AMPK primarily through Complex I inhibition in the mitochondria — mildly disrupting electron transport chain function, elevating the AMP:ATP ratio, and triggering AMPK activation downstream. This places metformin mechanistically in the same category as caloric restriction and exercise as AMPK activators — and is the primary biological rationale for exploring it as a longevity intervention.
THE CENTRAL TENSION
Metformin has the most compelling epidemiological longevity signal of any compound in this book — diabetics on metformin outliving healthy non-diabetics in the Bannister study; consistent associations with reduced cancer, cardiovascular events, and dementia in large epidemiological databases; a 2024 Cell paper showing 6.1-year brain aging regression in male primates. The mechanism is coherent: AMPK activation that partially mimics caloric restriction. The TAME trial is the most ambitious longevity pharmacology trial in history. And yet — multiple RCTs confirm that metformin blunts the mitochondrial and anabolic benefits of resistance exercise, creating a genuine trade-off for active individuals. The B12 depletion risk is real, cumulative, and still underappreciated in the community. And the TAME trial results are expected in the late 2020s — the most important pending longevity evidence in human pharmacology. Metformin may be the best longevity investment for sedentary, metabolically compromised, or older adults. It may actively undermine longevity strategy for young, lean, highly active individuals who are already exercising intensively. This dose-population-activity level nuance is the chapter.
GI adverse effects — nausea, diarrhea, abdominal cramping, metallic taste — affect approximately 20-30% of patients starting immediate-release metformin and are the most common reason for discontinuation. The mechanism: metformin accumulates in the gut epithelium at high local concentrations from oral dosing and affects intestinal glucose metabolism and bile acid signaling. Management: start at low dose (500 mg/day) and titrate up over weeks; take with meals; use extended-release (XR/ER) formulation — which reduces peak gut concentration and reduces GI adverse event rates by approximately 50% in clinical trials. Most GI effects improve within 2-4 weeks as tolerance develops.
Metformin impairs vitamin B12 absorption through a calcium-dependent mechanism in the ileum — it reduces intrinsic factor-mediated B12 uptake. This is cumulative: the longer the duration and higher the dose, the greater the B12 depletion risk. Clinical prevalence: depending on study methodology, 5-30% of long-term metformin users develop clinically significant B12 deficiency. Consequences of B12 deficiency: peripheral neuropathy (often irreversible if prolonged); subacute combined degeneration of the spinal cord; megaloblastic anemia; cognitive decline and dementia acceleration — particularly concerning in elderly longevity users. Management: B12 monitoring (serum B12 annually); B12 supplementation (1,000 mcg/day methylcobalamin preferred — the active form; or cyanocobalamin if cost is a concern). Some practitioners recommend calcium supplementation (calcium reverses the B12 absorption impairment) as an alternative or addition. For community longevity users, B12 supplementation should be considered standard alongside metformin.
Lactic acidosis was the defining adverse event that prevented metformin's earlier FDA approval (it was approved in Europe in the 1950s but the FDA delayed approval until 1995 in part due to concerns about phenformin-associated lactic acidosis; phenformin is a related biguanide that was withdrawn due to high lactic acidosis rates). Metformin itself has a very low lactic acidosis rate — estimated at 3-9 cases per 100,000 patient-years — the vast majority occurring in patients with contraindicated conditions: severe renal impairment (eGFR <30 mL/min), significant hepatic impairment, active heart failure, respiratory failure, or excessive alcohol use (conditions that impair lactate clearance). In patients without these contraindications, metformin's lactic acidosis risk is extremely low and should not be a concern for the healthy community longevity user. Renal function monitoring (eGFR) before and during metformin use is the primary safeguard.
Metformin is renally cleared (not metabolized) and accumulates in renal impairment, increasing lactic acidosis risk. Current FDA guidance: metformin is contraindicated if eGFR <30 mL/min/1.73m2; requires dose reduction consideration if eGFR 30-45; can be used with monitoring if eGFR 45-60. Baseline and periodic eGFR monitoring is required for all metformin users. For community longevity users: baseline eGFR before starting; annual monitoring thereafter; hold metformin if eGFR drops below 45 pending reassessment.
Metformin's primary pharmacological action at the cellular level is mild, reversible inhibition of mitochondrial Complex I (NADH dehydrogenase) — the first enzyme of the mitochondrial electron transport chain. This inhibition does not fully disrupt mitochondrial function at therapeutic doses; it produces a mild energy stress by increasing the AMP:ATP ratio (and AMP:ADP ratio) within the cell. This elevated AMP:ATP ratio is the primary signal that activates AMPK — the cell detects an energy shortage and responds by activating the catabolic AMPK pathway.
AMPK is a serine/threonine kinase that acts as a master energy sensor and metabolic switch. When activated: it inhibits mTORC1 (via phosphorylation of TSC2 and direct Raptor phosphorylation); it activates autophagy (via ULK1 phosphorylation — mTORC1 normally inhibits autophagy, so mTORC1 inhibition releases this brake); it reduces hepatic glucose output (primary therapeutic mechanism in T2D); it promotes fatty acid oxidation and reduces fatty acid synthesis; it reduces mitochondrial reactive oxygen species production; it activates SIRT1 (via NAD+ elevation); and it reduces NF-kB-mediated inflammatory signaling. Each of these downstream effects has independently been associated with longevity biology: autophagy induction, mTOR inhibition, inflammation reduction, ROS reduction, and SIRT1 activation. AMPK is often described as the 'metabolic master switch' that mimics the molecular state of caloric restriction — and metformin activates it at concentrations achievable with standard therapeutic doses.
Both metformin and rapamycin reduce mTORC1 activity, but through entirely different pathways. Rapamycin inhibits mTORC1 directly by forming the FKBP12-rapamycin inhibitory complex. Metformin inhibits mTORC1 indirectly through AMPK activation, which phosphorylates TSC2 (tuberous sclerosis complex 2) to activate it, and also directly phosphorylates Raptor. These are complementary mechanisms — in principle, combining metformin and rapamycin could produce greater mTORC1 inhibition than either alone through independent pathways. Whether this combination produces additive longevity benefit, redundant mTOR inhibition, or problematic over-inhibition in specific tissues (particularly muscle) is an active area of research. Community co-use of metformin and rapamycin is common in the evidence-based longevity community, but the combination has not been tested in a powered human longevity trial.
In T2D patients, metformin's most clinically relevant mechanism is reduction of hepatic gluconeogenesis — the liver's glucose production. This occurs partly through AMPK activation (which phosphorylates and inhibits gluconeogenic enzymes) and partly through AMPK-independent mechanisms including effects on mitochondrial energy metabolism. The result: reduced fasting glucose and improved glycemic control without significant risk of hypoglycemia (metformin does not stimulate insulin secretion, unlike sulfonylureas). For non-diabetic longevity users without gluconeogenesis excess, this hepatic effect is less relevant — the longevity mechanism in healthy individuals is primarily the AMPK/autophagy/mTOR pathway.
Bannister CA, Holden SE, Jenkins-Jones S, et al. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched non-diabetic controls. Diabetes, Obesity and Metabolism. 16(11):1165-1173. UK Clinical Practice Research Datalink; n=78,241 T2D patients on metformin vs n=78,341 non-diabetic controls; matched for age, sex, and comorbidities. Metformin group all-cause mortality HR: 0.85 (95% CI 0.81-0.90) vs non-diabetic controls — meaning diabetics on metformin died at 15% lower rate than matched healthy people. This is Grade C evidence — it is observational, subject to unmeasured confounding, and the study population is T2D patients rather than the longevity-target population of healthy older adults. The effect size and direction are nevertheless striking enough to have motivated the TAME trial.
TAME (Targeting Aging with Metformin; NCT03127514; Barzilai NJ et al.; Albert Einstein College of Medicine; NIH grant ~$65M). The first clinical trial with FDA agreement to use 'aging' itself as a primary indication endpoint — a regulatory milestone. Design: ~3,000 non-diabetic adults aged 65-79; metformin extended-release 1,500 mg/day vs placebo; target follow-up ~6 years; primary composite endpoint: any new age-related disease (cancer, cardiovascular disease, dementia, disability) or death. The regulatory significance: TAME's primary endpoint framework is designed to establish 'aging' as an approvable drug indication — creating a pathway for future anti-aging drug development beyond metformin specifically. Results expected late 2020s. Until TAME reports, there is no controlled human longevity endpoint trial data for metformin in non-diabetics.
A 2024 paper in Cell examined metformin's effects on biological aging markers in male primates. The compound slowed biological aging clocks, with a particularly notable finding of approximately 6.1-year regression in brain aging markers. This is one of the most striking non-human primate aging biology results published and significantly strengthens the translational case for metformin's longevity biology. Grade C (animal): non-human primate data is more translationally relevant than rodent data; brain aging marker regression is a particularly meaningful endpoint; human translation remains uncertain.
MILES (Metformin in Longevity Study; Barzilai et al.): short-term metformin in pre-diabetic individuals; primary focus on transcriptional changes in muscle biopsy samples. MILES confirmed that metformin induces measurable anti-aging transcriptional changes in human skeletal muscle: upregulation of autophagy-related genes; AMPK activation markers; gene expression patterns consistent with caloric restriction mimicry. This trial moved metformin longevity evidence from epidemiology into mechanism — showing the relevant biological pathways are actually activated by metformin in human muscle at therapeutic doses.
A 2025 study in the Journals of Gerontology examined data from the Women's Health Initiative: postmenopausal women with T2D who took metformin had a 30% lower risk of dying before age 90 compared with women taking sulfonylurea comparators. This exceptional longevity threshold analysis is consistent with the Bannister finding and adds to the epidemiological signal — suggesting metformin is associated with not just longer life but specifically with reaching exceptional longevity thresholds.
Evidence
Grade
Key Finding
Limitation
Bannister 2014 (Diab Obes Metab)
C — observational
T2D patients on metformin had 15% lower all-cause mortality than matched non-diabetic controls (HR 0.85)
Observational; confounding possible; T2D population not representative of healthy non-diabetics
MILES trial (mechanistic)
B — human RCT
Metformin induces anti-aging transcriptional changes in human skeletal muscle; AMPK/autophagy markers activated
Short-term; surrogate endpoints; mechanistic not clinical
2024 Cell primate study
C — animal
~6.1-year brain aging regression in male primates; biological aging clocks slowed
Non-human primate; translation to humans uncertain
2025 WHI analysis (J Gerontol)
C — observational
30% lower risk of dying before 90 in postmenopausal T2D women on metformin vs sulfonylurea
Observational; T2D population; sulfonylurea comparator not healthy controls
TAME trial (NCT03127514)
A — pending (RCT)
First FDA-recognized aging indication trial; ~3,000 non-diabetics 65-79; composite age-related disease endpoint; results late 2020s
Not yet reported; the most important pending longevity evidence
Exercise blunting (multiple RCTs, 2019-2026)
A — RCTs
Metformin attenuates mitochondrial biogenesis and muscle hypertrophy from resistance training in older adults
Active individuals may not benefit; longevity trade-off for exercising individuals
The most significant clinical controversy in metformin longevity use: multiple controlled trials have shown that metformin blunts the mitochondrial benefits of exercise — the very pathway through which exercise produces its longevity effects.
The exercise-metformin controversy emerged from multiple RCTs between 2019 and 2026. The defining study: Konopka et al. (published in multiple phases in JAMA Internal Medicine and related journals) — the MET-PREVENT trial and related work showed that in older adults, metformin use concurrent with resistance training attenuated: mitochondrial biogenesis (new mitochondria formed in response to exercise); muscle satellite cell activity (required for exercise-induced muscle hypertrophy); mTORC1-mediated protein synthesis in muscle; and the increase in VO2max from aerobic training. The mechanism: exercise activates AMPK and then, during the recovery phase, mTORC1 re-activates to drive the anabolic adaptations that make training beneficial. Metformin's sustained AMPK activation via Complex I inhibition suppresses mTORC1 during the recovery phase — blocking the anabolic signaling that translates exercise stress into adaptation.
A February 2026 systematic review (PMC12938515) synthesized the literature: 'randomized interventional trials in metabolically healthy older adults indicate that metformin can blunt resistance exercise–induced muscle hypertrophy and protein synthesis, likely through sustained activation of AMPK and consequent suppression of mTORC1 signaling.' The magnitude of the blunting effect varies across studies but is consistent enough in direction to be a genuine clinical concern. The practical implication: for an older adult who primarily pursues longevity through resistance and aerobic training, the exercise adaptation blunting may partially or fully offset metformin's other longevity benefits. For a sedentary older adult or one whose primary longevity tools are dietary and metabolic rather than exercise-based, the trade-off is less relevant.
THE EXERCISE TRADE-OFF — WHO METFORMIN IS BEST FOR
Best candidates for metformin longevity use: (1) Adults with prediabetes, insulin resistance, or metabolic syndrome — for these individuals, metformin addresses existing pathology while providing longevity mechanisms; (2) Sedentary or moderately active older adults (>50) who are not engaged in systematic high-intensity resistance training; (3) Adults with family history of cancer, cardiovascular disease, or dementia — consistent epidemiological associations between metformin use and reduced incidence of all three. Less appropriate candidates: (4) Young (<40), lean, metabolically healthy individuals whose primary longevity investment is intensive resistance training and cardiovascular fitness — the exercise blunting trade-off is most relevant here; (5) Competitive athletes in strength or endurance sports — potential impairment of training adaptations.
FDA-approved indications: type 2 diabetes mellitus (primary); prediabetes prevention (ADA-supported, CDC recognized, technically off-label for FDA but standard practice); polycystic ovary syndrome (PCOS) off-label. Community longevity use is off-label — prescribing metformin for healthy aging without a diabetes or prediabetes indication is outside the FDA-approved label. However, many longevity-oriented physicians prescribe metformin for community longevity applications using their prescriptive authority, particularly for patients with prediabetes, metabolic syndrome, family history of T2D, or documented insulin resistance — populations where the indication boundary between diabetes prevention and longevity is genuinely blurred.
Immediate release (IR): Glucophage and generics; 500 mg, 850 mg, 1000 mg tablets; taken with meals bid-tid; higher peak gut concentrations; more GI adverse effects. Extended release (ER/XR): Glucophage XR and generics; 500 mg, 750 mg, 1000 mg tablets; once-daily dosing; lower peak gut concentration; significantly fewer GI adverse effects; preferred by most community longevity users and now recommended by many practitioners for better tolerability. The standard longevity protocol: start with ER 500 mg once daily with dinner; titrate to 1,000-1,500 mg/day over 4-8 weeks based on tolerance. The TAME trial uses 1,500 mg/day of extended-release formulation.
Protocol
Dose
Formulation
Target Population
Conservative start
500 mg once daily with dinner
Extended release
Any new metformin user; older adults; history of GI sensitivity
Standard longevity
1,000 mg once daily with dinner
Extended release
Community longevity use in adults >50 with metabolic risk factors
TAME trial dose
1,500 mg/day (750 mg twice daily)
Extended release
Non-diabetic adults 65-79; the evidence-based longevity trial dose
Standard T2D
1,500-2,550 mg/day in divided doses
IR or ER
Diabetes management; highest doses for T2D not always appropriate for longevity use without supervision
The three most discussed longevity interventions in the evidence-based community are exercise, metformin, and rapamycin. Understanding how they interact is essential for community longevity protocol design.
Parameter
Exercise
Metformin
Rapamycin
Primary AMPK activation
Direct — immediate AMPK during activity; mTORC1 activation in recovery for muscle building
Direct via Complex I inhibition — sustained AMPK activation; sustained mTORC1 suppression
Indirect — rapamycin suppresses mTORC1 directly; AMPK not primarily affected
mTORC1 effect
Temporarily inhibited during exercise; re-activates to drive anabolic adaptation in recovery
Sustained suppression via AMPK; blunts recovery mTORC1 re-activation = muscle adaptation blunting
Direct sustained inhibition; most potent mTOR suppressor in this group
Autophagy
Stimulated during and after exercise
Stimulated via AMPK pathway
Stimulated via mTOR inhibition — most direct and potent autophagy activation
Muscle mass
Increases with training (mTORC1-dependent)
May reduce exercise-induced hypertrophy; maintained in sedentary individuals
Potentially reduces muscle protein synthesis at higher doses; net neutral to mildly catabolic over time
Interaction
N/A
Blunts exercise mitochondrial adaptation — the central controversy
May also blunt some exercise adaptations; less studied than metformin-exercise interaction
ITP mouse lifespan data
N/A (behavioral; not tested in ITP)
Not tested in NIA ITP
Most robust ITP lifespan extension
Human longevity evidence
Best: overwhelming epidemiological and mechanistic evidence
Strongest epidemiological signal (Bannister); TAME pending
PEARL trial safety/lean mass; ITP mouse data most robust
Best for whom
All ages; cornerstone of longevity; never replaced by drugs
Sedentary/metabolic risk individuals; older adults (>60); metabolic syndrome; prediabetes
Any age with physician oversight; most compelling for its preclinical evidence
The Bannister finding is compelling but not proof of causality. Observational studies have multiple potential confounders: healthy user effect (patients who take their medications are generally more health-conscious); the comparison to non-diabetic controls doesn't control for all metabolic differences; the T2D population has different baseline disease burden than healthy longevity users. The TAME trial is specifically designed to determine whether the Bannister signal reflects true pharmacological longevity benefit in non-diabetics. Until TAME reports, the observational data is hypothesis-generating not proof-of-longevity.
Multiple RCTs indicate that concurrent metformin use and resistance training attenuates the mitochondrial and anabolic adaptations of training in older adults. For an active individual whose primary longevity investment is exercise, this interaction is a genuine concern. If metformin is being used alongside intensive resistance or aerobic training, the net benefit calculation is uncertain and the interaction is not 'good.' Some practitioners recommend taking metformin on rest days only during periods of intensive training, or timing metformin away from training to reduce the overlap of peak AMPK activation. Neither approach has been validated in controlled trials.
Phenformin caused lactic acidosis at clinically significant rates and was withdrawn. Metformin's lactic acidosis rate is approximately 3-9 cases per 100,000 patient-years — extremely rare and almost exclusively in patients with specific contraindicated conditions (severe renal impairment, hepatic failure, active heart failure, respiratory failure, excessive alcohol). In patients without these contraindications, metformin's lactic acidosis risk is negligible. This distinction between phenformin (high risk) and metformin (low risk) is one of the most important pharmacological clarifications in this book.
B12 depletion from chronic metformin use is cumulative, dose-dependent, and affects 5-30% of long-term users depending on study methodology. The consequences — peripheral neuropathy, subacute combined degeneration, cognitive decline — can be serious and some are partially irreversible if prolonged. For a 50-year-old starting metformin for longevity who plans to use it for 20+ years, B12 depletion is not a minor consideration. Annual serum B12 monitoring and daily methylcobalamin supplementation (1,000 mcg) are the minimum appropriate preventive measures.
Bannister CA, Holden SE, Jenkins-Jones S, et al. (2014). Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched non-diabetic controls. Diabetes, Obesity and Metabolism. 16(11):1165-1173. [The most compelling epidemiological finding; T2D patients on metformin had lower all-cause mortality than matched non-diabetic controls; HR 0.85; n=78,241.]
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. (2016). Metformin as a Tool to Target Aging. Cell Metabolism. 23(6):1060-1065. [The primary TAME trial rationale paper; laying out the geroscience case for metformin as the first anti-aging drug trial.]
TAME Trial: NCT03127514. Targeting Aging with Metformin. Albert Einstein College of Medicine. NIH-funded ~$65M. Metformin ER 1,500 mg/day in non-diabetic adults 65-79; composite age-related disease endpoint; ~6-year follow-up; results expected late 2020s.
Konopka AR, et al. (2019). Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 18(1):e12880. [First major RCT confirming metformin blunts mitochondrial biogenesis from aerobic training in older adults; the paper that launched the exercise-metformin controversy.]
PMC12938515. (2026). Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging. February 2026. [Most current systematic synthesis of metformin-exercise interaction literature; confirms blunting of exercise-induced muscle hypertrophy and protein synthesis in metabolically healthy older adults via sustained AMPK/mTORC1 suppression.]
Barzilai N, et al. MILES Trial (Metformin in Longevity Study). [Anti-aging transcriptional changes in human skeletal muscle biopsy samples; AMPK/autophagy markers activated; mechanistic evidence that metformin activates longevity-relevant pathways in human tissue.]
Cell (2024). [Metformin slowed biological aging clocks in male primates; ~6.1-year regression in brain aging markers; most significant non-human primate aging biology result for metformin; specific citation to be confirmed from primary publication.]
Metformin is the most evidence-supported longevity drug in human medicine that is not yet approved for longevity. It may be the most important drug being tested in an aging indication trial. The exercise trade-off and B12 depletion are real and require management.
The honest summary: metformin has the most compelling epidemiological longevity signal of any compound in this book (Bannister; WHI analysis; consistent associations across cancer, CVD, dementia), a mechanistically coherent pathway (AMPK activation; mTOR suppression; autophagy induction; ROS reduction), primate aging biology data showing biological aging clock regression, and the TAME trial — the most ambitious longevity pharmacology trial ever run — testing it in non-diabetic humans. The safety record is exceptional: 70+ years, tens of millions of patients, well-characterized risks that are manageable with standard monitoring. The primary concerns for community longevity use: the exercise blunting trade-off (real; matters most for highly active individuals); B12 depletion (real; cumulative; manageable with supplementation and monitoring); and the unresolved question of whether it extends longevity in non-diabetic healthy people rather than just in metabolically compromised T2D patients. The TAME trial will answer the most important question. Until it does, metformin is the longevity compound with the strongest existing evidence and the most important pending trial.
— End of Metformin —
THE PEPTIDE BIBLE | Metformin | For Research & Educational Purposes Only
Metformin (INN: metformin; Glucophage; generics): biguanide oral antidiabetic; derived from French lilac (Galega officinalis); FDA-approved 1995 for T2D; first-line T2D therapy. Most prescribed antidiabetic worldwide. Schedule: not controlled. WADA: not banned. MECHANISM: mitochondrial Complex I inhibition → AMP:ATP ratio↑ → AMPK activation → mTORC1 inhibition (via TSC2 phosphorylation and direct Raptor phosphorylation) + autophagy induction (via ULK1) + hepatic gluconeogenesis↓ + ROS↓ + inflammation (NF-kB)↓ + SIRT1 activation. Mimics caloric restriction at molecular level. vs RAPAMYCIN: both inhibit mTORC1; different pathways; potentially complementary. EPIDEMIOLOGY: BANNISTER 2014 (Diab Obes Metab): n=78,241 T2D patients on metformin vs 78,341 non-diabetic controls; HR 0.85 for all-cause mortality — T2D on metformin outlived healthy non-diabetics. 2025 WHI analysis (J Gerontol): 30% lower risk of dying before 90 in postmenopausal T2D women on metformin vs sulfonylurea. Consistent associations with reduced cancer, CVD, dementia across multiple epidemiological databases. PRIMATE DATA (2024, Cell): ~6.1-year brain aging regression; biological aging clocks slowed. TAME TRIAL (NCT03127514; Barzilai; Einstein; NIH ~$65M): first FDA-recognized aging indication trial; ~3,000 non-diabetics 65-79; metformin ER 1,500 mg/day; composite age-related disease endpoint; ~6-year follow-up; RESULTS EXPECTED LATE 2020s — most important pending longevity evidence in human pharmacology. MILES TRIAL: mechanistic; anti-aging transcriptional changes in human muscle biopsy; AMPK/autophagy markers activated. EXERCISE CONTROVERSY: multiple RCTs (2019-2026) confirm metformin blunts mitochondrial biogenesis and muscle hypertrophy from resistance training via sustained AMPK activation suppressing recovery mTORC1. Most relevant for active individuals; less relevant for sedentary. SAFETY: GI effects (20-30% IR; 50% reduction with ER; improve with food and titration); B12 depletion (5-30% long-term; peripheral neuropathy risk; annual B12 monitoring + methylcobalamin 1,000 mcg/day supplementation MANDATORY); lactic acidosis (3-9/100,000 patient-years; almost exclusively in renal/hepatic impairment contraindications; low risk in healthy users); renal function monitoring (eGFR baseline + annual; contraindicated eGFR <30; reduce consideration <45). PROTOCOL: ER 500 mg/day → titrate to 1,000-1,500 mg/day over 4-8 weeks; take with dinner; TAME uses 1,500 mg/day ER. BEST CANDIDATES: prediabetes/insulin resistance/metabolic syndrome; older adults >55 with metabolic risk; sedentary; family history cancer/CVD/dementia. LESS APPROPRIATE: young lean highly active individuals engaged in intensive resistance training.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.